Mallinckrodt plc’s (MNK) Terlipressin, which won the support of an FDA panel by a narrow margin in July, now awaits the final decision on September 12, 2020.Terlipressin is proposed for the treatment of adults with hepatorenal syndrome type 1, an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.On July 15, an FDA panel voted 8-7, recommending approval of Terlipressin. While the recommendations of the advisory committee are not binding, the FDA usually follows the panels’ advice.Terlipressin, under brand name Erliso, is approved for use outside the U.S. and Canada.Terlipressin plus albumin is said to be the recommended standard-of-care therapy for HRS-1 in many other countries, where Terlipressin is approved.Terlipressin came under Mallinckrodt’s fold following the acquisition of Ikaria Inc., a privately-held critical care company, in 2015.MNK closed Wednesday’s (Aug.26, 2020) trading at $1.60, up 7.38%.